STOCKSURGICAL & MEDICAL INSTRUMENTS & APPARATUSUpdated 2026-06-07
Here’s whether DexCom, Inc. (DXCM) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Neutral.
🔵
Neutral
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+1.98% over 10 days); 3-month momentum positive (+6.0%). Concerns: RSI 79 — overbought, elevated pullback risk; weak 1-year return of -15.0%. Currently 19.0% off its 52-week high. Score: +3/7.
DXCM is in a confirmed uptrend, trading above both its 50-day ($64.57) and 200-day ($67.65) moving averages. With an RSI of 78.8, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of -15.0% compares to +24.4% for SPY (trailed the market by 39.4%).
$10,000 invested 1 year ago→ $8,498 today
vs. S&P 500 (SPY) — same period trailed market by 39.4%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($67.65)
✓Above 50-day MA ($64.57)
!RSI(14) neutral zone (30–70) — currently 78.8
✗Positive return (-15.0%)
!Within 10% of period high (−19.0%)
Period Range $72.86
$54.11$89.98
RSI (14) 78.8
0 · OversoldOverbought · 100
Key Metrics
Price$72.86
Period Return-15.0%
Period High$89.98
Period Low$54.11
Drawdown−19.0%
MA-50$64.57
MA-200$67.65
RSI (14)78.8
Avg Volume (30d)6.6M
vs. SPYtrailed by 39.4%
Return Rank#835 of 1245
Trend Signals
Price is above the 200-day moving average ($67.65)